Skip to main content

Table 1 Clinical characteristics of the study population

From: Decreased circulating and neutrophil mediated VEGF-A165 release in stable long-term cardiac transplant recipients

Clinical variables CTx recipients ( n= 18) Healthy controls ( n= 35)
Age (years) 49.6 ± 3.1 49.3 ± 1.6
Male 18 (100%) 16 (46%)
Body mass index (kg/m2) 26.5 ± 0.8  
Donor age (years) 24.4 ± 3.2  
Time since transplantation (months) 145 ± 20  
Primary diagnosis; n (%)   
CAD 7 (39%)  
Cardiomyopathy 9 (50%)  
Other 2 (11%)  
Medical conditions post-transplant; n (%)   
Hypertension 12 (67%)  
Diabetes mellitus 5 (28%)  
Dyslipidemia 11 (61%)  
CAV 7 (39%)  
Medications; n (%)   
Statins 17 (94%)  
ACEi 5 (28%)  
ARBs 7 (39%)  
β-blockers 6 (33%)  
Calcium channel blockers 14 (78%)  
Immunosuppressive treatments; n (%)   
Cyclosporine A 1 (0.06%)  
Tacrolimus 15 (83%)  
Sirolimus 3 (17%)  
MMF/MPA 13 (72%)  
Prednisone   
 Yes (%) 4 (22%)  
 No (%) 14 (78%)  
  1. ACEi: Angiotensin-converting enzyme inhibitor; ARBs: angiotensin II receptor blockers; CAD: Coronary artery disease, CAV: Cardiac allograft vasculopathy, MMF: Mycophenolate mofetil; MPA: Mycophenolate acid; NYHA: New York heart association. variables are expressed as mean ± SEM and percentages.